CTOs on the Move

RootPath Genomics

www.rootpath.com

 
RootPath, Inc. is a Cambridge, MA-based early-stage biotechnology company focusing on next-generation immuno- and cell-therapy.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

RootPath Genomics raised $11M on 01/05/2020

Similar Companies

Entrinsic Bioscience

entrinsic bioscience is a recognized leader in the development, manufacturing and commercialization of disruptive, science-derived amino-acid technologies that are clinically-proven to deliver better health outcomes in a broad range of therapeutic areas including gut health, hydration, skin and respiratory health.

PharmaForm

PharmaForm is a leading specialty contract development and manufacturing organization focusing on oral and transmucosal dosage forms. Founded in 1996, PharmaForm has built a reputation for delivering novel and innovative solutions to challenging problems

Generate Biomedicines

Generate Biomedicines is the first drug generation company, pioneering a machine learning-powered generative biology platform with the ability to generate new drugs on demand across a wide range of biologic modalities. The platform can drastically improve the speed at which targets and therapeutics are identified and validated, the specificity of target engagement by generated proteins, and the cost of identifying and developing clinical candidates. The company`s platform represents a potentially fundamental shift in what`s possible in the field of therapeutic development, addressing key challenges of drug discovery and drastically expanding the available search space for novel biomedicines. Generate Biomedicines was founded by Flagship Pioneering after two years of foundational research in its Labs unit and launched in 2020.

Xcellerex

Xcellerex is a Marlborough, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Retrophin

Retrophin is a biopharmaceutical company focused on the discovery, acquisition, development and commercialization of drugs for the treatment of debilitating and often life-threatening diseases for which there are currently limited patient options.